<DOC>
	<DOCNO>NCT02272127</DOCNO>
	<brief_summary>Non-small-cell lung cancer ( NSCLC ) patient activate epidermal growth factor receptor ( EGFR ) mutation exquisitely sensitive epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) widely use advanced patient . Whether treatment EGFR-TKIs improve outcome patient resect NSCLC harbor EGFR mutation still investigate . This study aim observe compare efficacy safety intercalate combination chemotherapy plus icotinib patient undergo resection EGRF mutation-positive non-small cell lung cancer stagingⅠB ( high risk factor ) ⅢA .</brief_summary>
	<brief_title>Study Chemotherapy Plus Icotinib Treat EGFR Mutation-positive Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients undergo completely resection EGRF mutationpositive NSCLC Staging ⅠB ( high risk factor ) ⅢA PS＜2 Adequate hematological , biochemical organ function . Systemic anticancer therapy prior surgery , malignancy study , unstable illness , woman pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>EGFR tyrosine kinase inhibitor</keyword>
</DOC>